123 related articles for article (PubMed ID: 23499586)
1. Positive association of adiponectin with soluble thrombomodulin, von Willebrand factor and soluble VCAM-1 in dyslipidemic subjects.
Vaverkova H; Karasek D; Novotny D; Kovarova D; Halenka M; Slavik L; Frohlich J
Clin Biochem; 2013 Jun; 46(9):766-71. PubMed ID: 23499586
[TBL] [Abstract][Full Text] [Related]
2. Soluble intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 in asymptomatic dyslipidemic subjects.
Karasek D; Vaverkova H; Frysak Z; Halenka M; Jackuliakova D; Novotny D; Lukes J
Int Angiol; 2011 Oct; 30(5):441-50. PubMed ID: 21804483
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum adipocyte fatty acid-binding protein and endothelial/hemostatic markers in dyslipidemic subjects.
Karasek D; Vaverkova H; Frysak Z; Orsag J; Novotny D; Halenka M; Slavik L
Neuro Endocrinol Lett; 2012; 33 Suppl 2():26-31. PubMed ID: 23183506
[TBL] [Abstract][Full Text] [Related]
4. Prothrombotic markers in asymptomatic dyslipidemic subjects.
Karasek D; Vaverkova H; Halenka M; Jackuliakova D; Frysak Z; Slavik L; Novotny D
J Thromb Thrombolysis; 2011 Jan; 31(1):27-36. PubMed ID: 20640487
[TBL] [Abstract][Full Text] [Related]
5. Total adiponectin levels in dyslipidemic individuals: relationship to metabolic parameters and intima-media thickness.
Karasek D; Vaverkova H; Halenka M; Jackuliakova D; Frysak Z; Novotny D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):55-62. PubMed ID: 21475379
[TBL] [Abstract][Full Text] [Related]
6. Prehypertension in dyslipidemic individuals; relationship to metabolic parameters and intima-media thickness.
Karasek D; Vaverkova H; Halenka M; Jackuliakova D; Frysak Z; Orsag J; Novotny D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Mar; 157(1):41-9. PubMed ID: 23073522
[TBL] [Abstract][Full Text] [Related]
7. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia.
Karásek D; Vaverková H; Halenka M; Slavík L; Novotný D
Thromb Res; 2009; 123(3):466-75. PubMed ID: 18417194
[TBL] [Abstract][Full Text] [Related]
8. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
Cugno M; Mari D; Meroni PL; Gronda E; Vicari F; Frigerio M; Coppola R; Bottasso B; Borghi MO; Gregorini L
Br J Haematol; 2004 Jul; 126(1):85-92. PubMed ID: 15198737
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein B vs non-high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness.
Karasek D; Vaverkova H; Cibickova L; Gajdova J; Kubickova V
J Clin Lipidol; 2017; 11(2):442-449. PubMed ID: 28502501
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial.
de Jager J; Kooy A; Schalkwijk C; van der Kolk J; Lehert P; Bets D; Wulffelé MG; Donker AJ; Stehouwer CD
J Intern Med; 2014 Jan; 275(1):59-70. PubMed ID: 23981104
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosis.
Zhang Q; Zeng C; Fu Y; Cheng Z; Zhang J; Liu Z
Nephrology (Carlton); 2012 May; 17(4):338-45. PubMed ID: 22295953
[TBL] [Abstract][Full Text] [Related]
12. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.
Frijns R; Fijnheer R; Schiel A; Donders R; Sixma J; Derksen R
J Rheumatol; 2001 Mar; 28(3):514-9. PubMed ID: 11296951
[TBL] [Abstract][Full Text] [Related]
13. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.
Wållberg-Jonsson S; Cvetkovic JT; Sundqvist KG; Lefvert AK; Rantapää-Dahlqvist S
J Rheumatol; 2002 May; 29(5):875-82. PubMed ID: 12022343
[TBL] [Abstract][Full Text] [Related]
14. Markers of endothelial cell activation/injury: CD146 and thrombomodulin are related to adiponectin in kidney allograft recipients.
Małyszko J; Małyszko JS; Brzosko S; Wołczynski S; Myśliwiec M
Am J Nephrol; 2005; 25(3):203-10. PubMed ID: 15897668
[TBL] [Abstract][Full Text] [Related]
15. The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus.
Alizadeh Dehnavi R; Beishuizen ED; van de Ree MA; Le Cessie S; Huisman MV; Kluft C; Princen HM; Tamsma JT
Eur J Intern Med; 2008 Mar; 19(2):115-21. PubMed ID: 18249307
[TBL] [Abstract][Full Text] [Related]
16. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes.
Leurs PB; Stolk RP; Hamulyak K; Van Oerle R; Grobbee DE; Wolffenbuttel BH
Diabetes Care; 2002 Aug; 25(8):1340-5. PubMed ID: 12145232
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.
Wannamethee SG; Sattar N; Rumley A; Whincup PH; Lennon L; Lowe GD
Diabetes Care; 2008 May; 31(5):995-1000. PubMed ID: 18235054
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum von Willebrand factor, but not soluble ICAM and VCAM, for mortality and cardiovascular events is independent of residual renal function in peritoneal dialysis patients.
Dong J; Li YJ; Yang ZK; Xu R
Perit Dial Int; 2014; 34(7):706-13. PubMed ID: 24584618
[TBL] [Abstract][Full Text] [Related]
19. Association of cardiovascular risk factors with markers of endothelial dysfunction in middle-aged men and women. Results from the MONICA/KORA Augsburg Study.
Thorand B; Baumert J; Döring A; Schneider A; Chambless L; Löwel H; Kolb H; Koenig W
Thromb Haemost; 2006 Jan; 95(1):134-41. PubMed ID: 16543972
[TBL] [Abstract][Full Text] [Related]
20. Correlation between soluble markers of endothelial dysfunction in patients with renal failure.
Jacobson SH; Egberg N; Hylander B; Lundahl J
Am J Nephrol; 2002; 22(1):42-7. PubMed ID: 11919402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
